Laurent Bonello
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Laurent Bonello has a total of 209 co-authors. Here are the top co-authors by number of shared publications:
Franck Paganelli
Service de Cardiologie, Centre Hospitalier Universitaire de Marseille, Hôpital NORD, Aix-Marseille Université, Hôpital Nord, Marseille, France
34 shared publications- Marc Laine
Service de Cardiologie, Centre Hospitalier Universitaire de Marseille, Hôpital Nord, Aix-Marseille Université, Marseille, France
24 shared publications - Françoise Dignat-George
Aix-Marseille Univ, INSERM, INRAE, Centre de Recherche en CardioVasculaire et Nutrition Marseille, France (P.D., N.O., V.P., F.D.-G., G.H.).
23 shared publications Laurence Camoin-Jau
Service d'hématologie Biologique, Centre hospitalo-universitaire Timone, Assistance-Publique Hôpitaux de Marseille, Marseille, France
18 shared publications- Gilles Lemesle
Intensive Cardiac Care Unit, Heart and Lung Institute, CHU de Lille, Lille, 59000, France; Institut Pasteur of Lille, Inserm U1011, Lille, 59000, France; Université de Lille, Lille, 59000, France; French Alliance for Cardiovascular Trials (FACT), Paris, France
11 shared publications Corinne Frere
Department of Haematology, Assistance Publique Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France
10 shared publications
Latest Publications
- 1 June 2020
- Published by Elsevier in Archives of Cardiovascular Diseases
- Vol. 113 (6-7) , 448-460
Trials of mechanical circulatory support with percutaneous axial flow pumps in cardiogenic shock complicating acute myocardial infarction: Mission impossible?
- 1 June 2020
- Published by Elsevier in Archives of Cardiovascular Diseases
- Vol. 113 (6-7) , 448-460
Trials of mechanical circulatory support with percutaneous axial flow pumps in cardiogenic shock complicating acute myocardial infarction: Mission impossible?
- 1 October 2018
- Published by Elsevier in Archives of Cardiovascular Diseases
- Vol. 111 (10) , 601-612
Mechanical circulatory support in patients with cardiogenic shock in intensive care units: A position paper of the “Unité de Soins Intensifs de Cardiologie” group of the French Society of Cardiology, endorsed by the “Groupe Athérome et Cardiologie Interventionnelle” of the French Society of Cardiology
- 1 October 2018
- Published by Elsevier in Archives of Cardiovascular Diseases
- Vol. 111 (10) , 601-612
Mechanical circulatory support in patients with cardiogenic shock in intensive care units: A position paper of the “Unité de Soins Intensifs de Cardiologie” group of the French Society of Cardiology, endorsed by the “Groupe Athérome et Cardiologie Interventionnelle” of the French Society of Cardiology
- 20 September 2018
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 118 (10) , 1839-1846
Meta-Analysis of Potent P2Y12-ADP Receptor Antagonist Therapy Compared to Clopidogrel Therapy in Acute Coronary Syndrome Patients with Chronic Kidney Disease
Background The clinical benefit of anti-platelet agents in patients with chronic kidney disease (CKD) is uncertain. In addition, the risk–benefit ratio of potent oral P2Y12-adenosine diphosphate (ADP) receptor antagonists (PPAs), namely, prasugrel and ticagrelor, compared with clopidogrel in CKD patients suffering from acute coronary syndrome (ACS) remains unknown. Objective We performed a meta-analysis of all studies comparing the clinical outcomes of PPA and clopidogrel therapy in CKD patients suffering from ACS. Methods We searched PubMed, the Cochrane library, Google Scholar, Clinical trial.org and the abstracts of international cardiology congresses from April 2000 to October 2017. Clinical studies comparing PPA with clopidogrel in ACS patients with CKD were selected. Our literature research identified five studies which were included in the meta-analysis. The primary endpoint was a composite of major adverse cardiovascular events (MACEs) at the latest follow-up available. Secondary endpoint included bleedings. Results We included data from three sub-group analysis of randomized clinical trials and two prospective observational studies (n = 31,234). Overall, PPAs were associated with lower rates of major cardiovascular events, with a pooled hazard ratio (pHR) of 0.88 (95% confidence interval [CI]: 0.79–0.99; p = 0.03), without increased bleedings (pHR = 1.10) (95% CI: 0.95–1.27; p = 0.18). In a sensitivity analysis restricted to studies enrolling invasively managed patients, the benefit of PPA on MACE was maintained (pHR = 0.85) (95% CI: 0.77–0.93; p < 0.001), including a reduction in mortality (pHR = 0.82) (95% CI: 0.7–0.96; p = 0.016). Conclusion Compared with clopidogrel, PPAs were associated with a reduced rate of MACE without increased bleedings in CKD patients with ACS. Among invasively managed patients, this benefit from PPA included a reduction in mortality.
- 20 September 2018
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 118 (10) , 1839-1846
Meta-Analysis of Potent P2Y12-ADP Receptor Antagonist Therapy Compared to Clopidogrel Therapy in Acute Coronary Syndrome Patients with Chronic Kidney Disease
Background The clinical benefit of anti-platelet agents in patients with chronic kidney disease (CKD) is uncertain. In addition, the risk–benefit ratio of potent oral P2Y12-adenosine diphosphate (ADP) receptor antagonists (PPAs), namely, prasugrel and ticagrelor, compared with clopidogrel in CKD patients suffering from acute coronary syndrome (ACS) remains unknown. Objective We performed a meta-analysis of all studies comparing the clinical outcomes of PPA and clopidogrel therapy in CKD patients suffering from ACS. Methods We searched PubMed, the Cochrane library, Google Scholar, Clinical trial.org and the abstracts of international cardiology congresses from April 2000 to October 2017. Clinical studies comparing PPA with clopidogrel in ACS patients with CKD were selected. Our literature research identified five studies which were included in the meta-analysis. The primary endpoint was a composite of major adverse cardiovascular events (MACEs) at the latest follow-up available. Secondary endpoint included bleedings. Results We included data from three sub-group analysis of randomized clinical trials and two prospective observational studies (n = 31,234). Overall, PPAs were associated with lower rates of major cardiovascular events, with a pooled hazard ratio (pHR) of 0.88 (95% confidence interval [CI]: 0.79–0.99; p = 0.03), without increased bleedings (pHR = 1.10) (95% CI: 0.95–1.27; p = 0.18). In a sensitivity analysis restricted to studies enrolling invasively managed patients, the benefit of PPA on MACE was maintained (pHR = 0.85) (95% CI: 0.77–0.93; p < 0.001), including a reduction in mortality (pHR = 0.82) (95% CI: 0.7–0.96; p = 0.016). Conclusion Compared with clopidogrel, PPAs were associated with a reduced rate of MACE without increased bleedings in CKD patients with ACS. Among invasively managed patients, this benefit from PPA included a reduction in mortality.
- Open Access
- 6 March 2018
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 7 (5)
To Have and Have Not: Intrinsic Platelet Hyperreactivity?
- 6 March 2018
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 7 (5)
Open AccessTo Have and Have Not: Intrinsic Platelet Hyperreactivity?
- Open Access
- 1 January 2018
- Published by Elsevier in The Lancet
- Vol. 391 (10118) , 306
Great expectations
- 1 January 2018
- Published by Elsevier in The Lancet
- Vol. 391 (10118) , 306
Open AccessGreat expectations
- 1 August 2017
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 10 (16) , 1618-1620
Platelet Reactivity
- 1 August 2017
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 10 (16) , 1618-1620
Platelet Reactivity
- 1 November 2016
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 9 (22) , 2267-2276
Timing of Coronary Invasive Strategy in Non–ST-Segment Elevation Acute Coronary Syndromes and Clinical Outcomes
- 1 November 2016
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 9 (22) , 2267-2276
Timing of Coronary Invasive Strategy in Non–ST-Segment Elevation Acute Coronary Syndromes and Clinical Outcomes
- 1 October 2016
- Published by Elsevier in International Journal of Cardiology
- Vol. 220, 496-500
Potential mechanism of acute stent thrombosis with bivalirudin following percutaneous coronary intervention in acute coronary syndromes
- 1 October 2016
- Published by Elsevier in International Journal of Cardiology
- Vol. 220, 496-500
Potential mechanism of acute stent thrombosis with bivalirudin following percutaneous coronary intervention in acute coronary syndromes
- 26 May 2016
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 42 (2) , 294-295
In dubious battle: bleeding versus ischemic events
- 26 May 2016
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 42 (2) , 294-295
In dubious battle: bleeding versus ischemic events